Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling,nausea and fatigue.Myocardial fibrosis, also known as myocardial calcification, is the result of sustained myocardial fiber and/or repeated aggravation of myocardial ischemia and hypoxia caused by moderate to severe coronary atherosclerotic stenosis, leading to the progressive development of heart failure with IHD, or chronic ischemic heart disease
This report contains market size and forecasts of Myocardial Fibrosis in Global, including the following market information:
Global Myocardial Fibrosis Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Myocardial Fibrosis market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Small Molecule Therapeutic Modality Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myocardial Fibrosis include Merck, Evotec AG, Miragen Therapeutics, TRACON Pharmaceuticals, Daewoong Pharmaceutical, Galectin Therapeutics, GTx, Invivosciences and Lead Discovery Center and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Myocardial Fibrosis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myocardial Fibrosis Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Myocardial Fibrosis Market Segment Percentages, by Type, 2021 (%)
Small Molecule Therapeutic Modality
Protein Therapeutic Modality
Peptide Therapeutic Modality
Endoglin Antibody Therapeutic Modality
Stem Cell Therapeutic Modality
RNA Therapeutic Modality
Other
Global Myocardial Fibrosis Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Myocardial Fibrosis Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinics
Research Laboratories
Global Myocardial Fibrosis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Myocardial Fibrosis Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myocardial Fibrosis revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Myocardial Fibrosis revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Evotec AG
Miragen Therapeutics
TRACON Pharmaceuticals
Daewoong Pharmaceutical
Galectin Therapeutics
GTx
Invivosciences
Lead Discovery Center
MandalMed